Cargando…

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?

PURPOSE: The addition of two years of abemaciclib treatment to standard adjuvant endocrine therapy in all patients with high risk ER+, HER2- early breast cancer (EBC) has been approved by the US Food and Drug Administration (FDA). Pre-selection of patients with an immediate risk of recurrence within...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jongbloed, Elisabeth M, Blommestein, Hedwig M, van Schoubroeck, Hannah M, Martens, John W M, Wilting, Saskia M, Uyl-de Groot, Carin A, Jager, Agnes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940501/ https://www.ncbi.nlm.nih.gov/pubmed/36814469 http://dx.doi.org/10.2147/BCTT.S387375

Ejemplares similares

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients
por: Jongbloed, Elisabeth M., et al.
Publicado: (2021)

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
por: Chen, Yi Hsuan, et al.
Publicado: (2023)

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review
por: Chen, Yi Hsuan, et al.
Publicado: (2022)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
por: Blommestein, Hedwig M., et al.
Publicado: (2019)

Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)
por: Verelst, Silvia G.R., et al.
Publicado: (2018)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Real‐world evidence in health technology assessment of high‐risk medical devices: Fit for purpose?
por: Klein, Philip, et al.
Publicado: (2022)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach
por: Clarijs, Marloes E., et al.
Publicado: (2021)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

Commentary: One artery does not fit all: Tailoring the operation to the patient
por: Lawton, Jennifer S.
Publicado: (2021)

Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity
por: Wang, Boshi, et al.
Publicado: (2022)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Abemaciclib for breast cancer
Publicado: (2020)

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab
por: Franken, Margreet, et al.
Publicado: (2020)

Time to Tailor the One-Size-Fits-All Approach?
por: Kuindersma, Marnix, et al.
Publicado: (2021)

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
por: Bakker, LJ, et al.
Publicado: (2023)

A tale on rabbit ears and pan-handles, the rings that rule all
por: Smid, Marcel, et al.
Publicado: (2019)

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels
por: Jongbloed, Elisabeth M., et al.
Publicado: (2023)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Reply to Kuindersma and Spronk: Time to Tailor the One-Size-Fits-All Approach?
por: Furfaro, David M., et al.
Publicado: (2021)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

A Likely Case of Abemaciclib-Induced Hyperpigmentation in a Patient With Metastatic Breast Cancer
por: Salusti-Simpson, Michela, et al.
Publicado: (2022)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Tailoring Release Protocols to Individual Species and Sites: One Size Does Not Fit All
por: Moseby, Katherine E., et al.
Publicado: (2014)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
por: Ciani, Oriana, et al.
Publicado: (2021)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
por: Braal, C. Louwrens, et al.
Publicado: (2022)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Lost by Transcription: Fork Failures, Elevated Expression, and Clinical Consequences Related to Deletions in Metastatic Colorectal Cancer
por: Smid, Marcel, et al.
Publicado: (2022)

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
por: Tate, Sonya C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ojf7lq17f7oakjhj1pugnomvhu